ASTRAZENECA on Thursday (18) cemented its lead in bringing a preventative Covid-19 shot for the non-infected to market for people who do not respond well to vaccines, saying its antibody drug cocktail offered 83 per cent protection over six months.
The injected therapy, called AZD7442 or Evusheld, had previously been shown to confer 77 per cent protection against symptomatic illness after three months, in an earlier readout of the late-stage PROVENT trial in August.
The Anglo-Swedish company also said a separate study in patients with mild-to-moderate Covid-19 showed a higher dose of AZD7442 cut the risk of symptoms worsening by 88 per cent when given within three days of first symptoms.
The latest results from longer-term follow-ups potentially position AstraZeneca, like rival Pfizer as a future supplier of both Covid-19 vaccines and treatments, with AstraZeneca having said the therapy's "real advantage" was as a preventative shot.
"These new data add to the growing body of evidence supporting AZD7442's potential to make a significant difference in the prevention and treatment of Covid-19," executive vice-president Mene Pangalos said in a statement.
(Reuters)
